Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor
in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4
inhibitor
Phase:
Phase 4
Details
Lead Sponsor:
The Catholic University of Korea
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate